SSTR2 and neoplasm: SSTR2 expression was not associated with 5-year OS (estimated 66.3% [95% CI: 34.4%-98.2%], 67.9% [95% CI: 41.7%-94.1%], 69.2% [53.5%-84.9%] for patients with ≥ 50%, 1-49%, <1% tumor cells expressing SSTR2, respectively; p=0.71 for <1% vs 1-100% SSTR2 expression; p=0.96 for ≥ 50% vs 1-49% SSTR2 expression).